Smart investors can spot trends. They can predict what will happen next and anyone who is paying attention knows that the marijuana industry is booming, expanding, and thriving. In fact, conservative estimates predict that the industry is expected to be worth 21 billion dollars by the end of 2020. Welcome to the Green Rush, where anyone with a bit of foresight and capital can get in on this rapidly growing industry. It should be noted, that not all investments are equal in merit. It is then important for investors to recognize innovative ideas and to capitalize on emerging trends.
Enter: MyDx, Inc. (OTCQB:MYDX) a science and technology company based in San Diego, California, that has created MyDx, the world’s first portable, handheld, chemical analyzer for consumers. Our first sensor, CannaDx, is capable of analyzing cannabis samples for potency and medical viability (cannabinoids, such as THC, and terpenes) and our other sensors, AquaDx, OrganaDx, and AeroDx, are currently being developed by our R&D Team.
Our vision is simple: empower users to Trust and Verify™ what they put into their minds and bodies. Whether that is food, water, air, or cannabis – we believe that everyone should have the right to know exactly what they are consuming. MyDx utilizes electronic nose nanotechnology – allowing our various sensors to detect certain compounds of interest. This information is then relayed to the user’s smart phone using the MyDx App where it is interpreted and explained to the user by our company mascot, MollieCule.
This publicly traded science and technology company is the perfect opportunity for investors looking to purchase marijuana stocks. MyDx is a safer bet than directly investing in the cannabis industry for two reasons: MyDx does not manufacture or handle any marijuana (which is still illegal on the federal level) and because this company isn’t limited to cannabis applications. Our air, water, and food sensors will ensure access to a diverse, robust, and broad market.
Potential cannabis stock investors who believe in the medicinal benefits of cannabis should view MyDx as an ideal investment. In our aim to legitimize cannabis as a medicine, we are working to compile a crowd-sourced and HIPPA-protected database where users can predict how a cannabis sample will make them feel or what symptoms it will relieve. We believe that this database will serve as the framework for future clinical trials and cannabis research. We are also seeking partnerships with institutions currently evaluating the medicinal qualities of cannabis.
All of this puts MyDx at the forefront of cannabis testing and use – while at the same time not limiting its potential to one market. This makes MyDx an excellent opportunity for investors who have been sitting on the sidelines because they are worried about the perceived volatility and risk associated with the cannabis industry. Health conscious consumers will undoubtedly look to purchase personal analyzers and naturally a market will arise to meet these needs. As of today, MyDx is poised to lead and dominate the personal analyzer market, making it an ideal marijuana stock for investors looking to capitalize on the Green Rush. The lack of regulation among cannabis testing labs and the demand for user operated personal cannabis testing kits ensures that MyDx will have vitality in the cannabis industry and beyond.
Go to our site and take a look at our video. It will explain just how simple and easy it is to use MyDx to test cannabis samples and the MyDx White Paper will explain all of the technical nuance utilized by this innovative device.